Physicians and academic researchers at the Center for Liver Disease and Transplantation share a deep commitment to clinical innovation. Many of the Center's studies address hepatitis C, which is the leading indication for transplantation and a major cause of organ failure after transplantation.
NewYork-Presbyterian Hospital investigators have participated in virtually every clinical trial of new hepatitis C drugs which have revolutionized the treatment of this infection and increase the likelihood of cure.
Our research protocols include studies of:
- Hepatitis B and C therapy, both before and after transplant
- Immunosuppressive therapy for liver transplantation
- Techniques for predicting likelihood of organ rejection
- Advanced organ preservation methods
- Measures of outcomes in liver disease
- Liver transplantation without chronic immunosuppression (immune tolerance)